Topic: Boston Scientific Corporation
CHICAGO (Reuters) - U.S. health regulators said they are still investigating a rare but serious problem with Boston Scientific Corp's new heart stents and required the company to caution doctors about it when the device was approved last month.The Food and Drug ...
(Reuters) - Health regulators are investigating a rare but potentially serious problem with a newer class of heart stents that causes the tiny tubular devices made of wire mesh to shrink, or lengthen, after implantation.The problem appears to occur most frequently in ...
(Reuters) - Health regulators are investigating a rare but potentially serious problem with a newer class of heart stents that causes the tiny tubular devices made of wire mesh to shrink, or lengthen, after implantation.The problem appears to occur most frequently in ...
(Reuters) - Health regulators are investigating a rare but potentially serious problem with a newer class of heart stents that causes the tiny tubular devices made of wire mesh to shrink, or lengthen, after implantation.The problem appears to occur most frequently in ...
(Reuters) - A federal appeals court said Boston Scientific Corp did not infringe a patent by Johnson & Johnson's Cordis unit related to a stent used to treat coronary artery disease, but could not block the enforcement of two patents.Wednesday's ruling in ...
CHICAGO (Reuters) - Women derive twice the benefit from a device to treat heart failure as men, U.S. researchers said on Monday, underscoring the different ways in which men and women experience heart disease.Women treated with a combination pacemaker and defibrillator device ...
Recently, leading medical devices company, Boston Scientific (BSX), decided to acquire California-based Sadra Medical, a development stage company. Apart from an upfront payment of $225 million, Boston Scientific is liable to pay another $225 million on achievement of certain milestones through 2016. ...
Boston Scientific Corporation (BSX) Investor Day Conference Call November 19, 2010 8:00 am ET. Boston Scientific and I'd just use DES here as the example, served market share in developed markets is 31% compared to 6% in emerging markets. Now Dr. Dawkins ...
ANP) announced that its corporate partner, Boston Scientific Corporation (NYSE: MDCO), is designed to determine the safety and efficacy of the TAXUS(R) Express(2)(TM) Paclitaxel-Eluting Coronary Stent System compared to bare-metal stenting in patients experiencing an acute myocardial infarction (AMI), or heart attack. ...
BSX) today announced three-year follow-up data from the HORIZONS-AMI trial. After three years follow-up, the primary efficacy endpoint of ischemia-driven target lesion revascularization (TLR) was 9.4 percent for patients treated with TAXUS Express vs. 15.1 percent for bare-metal Express (p The primary ...
From Around the Web
Video Gallery
-
PROMUS Element™ Plus Stent System
Boston Scientific Corporation (NYSE:BSX) announces US Food and Drug ...2011-11-23 -
Boston Scientific Q2 Earnings Top Estimates ...
Boston Scientific (NYSE:BSX) reported Q2 EPS of $0.17 ...2011-07-28 -
Non-Drug Therapy for Asthma Sufferers
Boston Scientific Corporation (NYSE: BSX) announces positive clinical data from ...2011-09-27
